260 related articles for article (PubMed ID: 23403239)
41. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
42. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
43. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
[TBL] [Abstract][Full Text] [Related]
44. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
45. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
[TBL] [Abstract][Full Text] [Related]
46. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
47. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
48. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation.
Sia IG; Wilson JA; Groettum CM; Espy MJ; Smith TF; Paya CV
J Infect Dis; 2000 Feb; 181(2):717-20. PubMed ID: 10669361
[TBL] [Abstract][Full Text] [Related]
49. Human cytomegalovirus and kidney transplantation: a clinician's update.
De Keyzer K; Van Laecke S; Peeters P; Vanholder R
Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
51. Human beta-herpesvirus interactions in solid organ transplant recipients.
Mendez JC; Dockrell DH; Espy MJ; Smith TF; Wilson JA; Harmsen WS; Ilstrup D; Paya CV
J Infect Dis; 2001 Jan; 183(2):179-184. PubMed ID: 11120923
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
53. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
[TBL] [Abstract][Full Text] [Related]
54. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
55. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
[TBL] [Abstract][Full Text] [Related]
56. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.
Díaz-Pedroche C; Lumbreras C; San Juan R; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno-Elola A; Hernando S; Moreno-González E; Aguado JM
Transplantation; 2006 Jul; 82(1):30-5. PubMed ID: 16861938
[TBL] [Abstract][Full Text] [Related]
57. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
58. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
La Rosa C; Limaye AP; Krishnan A; Blumstein G; Longmate J; Diamond DJ
Transpl Int; 2011 Sep; 24(9):920-31. PubMed ID: 21672050
[TBL] [Abstract][Full Text] [Related]
59. Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Marshall Lyon G; Silveira FP; Wagener MM; Limaye AP
J Infect Dis; 2022 Feb; 225(3):436-442. PubMed ID: 33755176
[TBL] [Abstract][Full Text] [Related]
60. Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients.
Kamar N; Mengelle C; Yahyaoui S; Sandres-Sauné K; Durand D; Izopet J; Rostaing L
J Clin Virol; 2005 May; 33(1):35-42. PubMed ID: 15797363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]